Cargando…
A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA
All the currently used type A botulinum neurotoxins for clinical uses are of subtype A1. We compared the efficacy and safety for the first time head-to-head between a novel botulinum toxin A2NTX prepared from subtype A2 and onabotulinumtoxinA (BOTOX) derived from A1 for post-stroke spasticity. We as...
Autores principales: | Kaji, Ryuji, Miyashiro, Ai, Sato, Nori, Furumoto, Taiki, Takeuchi, Toshiaki, Miyamoto, Ryosuke, Kohda, Tomoko, Izumi, Yuishin, Kozaki, Shunji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697926/ https://www.ncbi.nlm.nih.gov/pubmed/36355989 http://dx.doi.org/10.3390/toxins14110739 |
Ejemplares similares
-
Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins
por: Takeuchi, Toshiaki, et al.
Publicado: (2021) -
Treatment of adult spasticity with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Esquenazi, Alberto, et al.
Publicado: (2023) -
OnabotulinumtoxinA muscle injection patterns in adult spasticity: a systematic literature review
por: Nalysnyk, Luba, et al.
Publicado: (2013) -
Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial
por: Devier, Deidre, et al.
Publicado: (2017) -
OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)